S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 10, 2013, Pages

  Anania, Maria Chiara ^a   Miranda, Claudia ^a   Vizioli, Maria Grazia ^a   Mazzoni, Mara ^a   Cleris, Loredana ^b   Pagliardini, Sonia ^a   Manenti, Giacomo ^c   Borrello, Maria Grazia ^a   Pierotti, Marco Alessandro ^a   Greco, Angela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Division of Chemoprevention   (Italy)

^c Unit of Epidemiology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CELL STRAIN 3T3; CONTACT INHIBITION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; S100A11 GENE; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; UPREGULATION;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; S100 PROTEINS; THYROID NEOPLASMS; UP-REGULATION;

EID: 84885199056     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1652     Document Type: Article

References (37)

1. Davies L, Welch HG Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295: 2164-2167.
2. Gild ML, Bullock M, Robinson B.G., Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol. 2011; 7: 617-624.
3. Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol. 2011; 24(SUPPL. 2): S44-S52.
4. Greco A, Borrello MG, Miranda C, Degl'Innocenti D, Pierotti MA. Molecular pathology of differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2009; 53(5): 440-453.
5. Salama I, Malone PS, Mihaimeed F, Jones JL A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008; 34: 357-364.
6. He H, Li J, Weng S., Li M, Yu Y. S100A11: diverse function and pathology corresponding to different target proteins. Cell Biochem Biophys. 2009; 55: 117-126.
7. Sakaguchi M, Miyazaki M, Inoue Y., et al Relationship between contact inhibition and intranuclear S100C of normal human fibro-blasts. J Cell Biol. 2000; 149: 1193-1206.
8. Bianchi R, Giambanco I, Arcuri C., Donato R. Subcellular localization of S100A11 (S100C) in LLC-PK1 renal cells: calcium- and protein kinase C-dependent association of S100A11 with S100B and vimentin intermediate filaments. Microsc Res Tech. 2003; 60: 639-651.
9. Murzik U, Hemmerich P, Weidtkamp-Peters S, et al Rad54B targeting to DNA double-strand break repair sites requires complex formation with S100A11. Mol Biol Cell. 2008; 19: 2926-2935.
10. Sakaguchi M, Huh NH S100A11, a dual growth regulator of epidermal keratinocytes. Amino Acids. 2011; 41: 797-807.
11. Rust R, Visser L, Harms G., et al. High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma. Br J Haematol. 2005; 131: 596-608.
12. Wang G, Wang X, Wang S., et al Colorectal cancer progression correlates with upregulation of S100A11 expression in tumor tissues. Int J Colorectal Dis. 2008; 23: 675-682.
13. Kondo A, Sakaguchi M, Makino E., Namba M, Okada S, Huh NH Localization of S100C immunoreactivity in various human tissues. Acta Med Okayama. 2002; 56: 31-34.
14. Ji J, Zhao L, Wang X., et al Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004; 130: 480-486.
15. Memon AA, Sorensen BS, Meldgaard P, Fokdal L., Thykjaer T, Nexo E. Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin Cancer Res. 2005; 11: 606-611.
16. Jarzab B, Wiench M, Fujarewicz K., et al Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005; 65: 1587-1597.
17. Finn SP, Smyth P, Chill S., et al Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch. 2007; 450: 249-260.
18. Stolf BS, Abreu CM, Mahler-Araujo MB, et al. Expression profile of malignant and non-malignant diseases of the thyroid gland reveals altered expression of a common set of genes in goiter and papillary carcinomas. Cancer Lett. 2005; 227: 59-73.
19. Torres-Cabala C., Panizo-Santos A, Krutzsch H.C., et al Differential expression of S100C in thyroid lesions. Int J Surg Pathol. 2004; 12: 107-115.
20. Torres-Cabala C., Bibbo M, Panizo-Santos A, et al Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol. 2006; 50: 518-528.
21. Anania MC, Sensi M, Radaelli E., et al TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. Oncogene. 2011; 30: 3011-3023.
22. Mori M, Shimada H, Gunji Y., et al S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer. Oncol Rep. 2004; 11: 1287-1293.
23. Tian T, Hao J, Xu A., et al Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci. 2007; 98: 1265-1274.
24. Huang Y, Prasad M, Lemon W.J., et al Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001; 98(26): 15044-15049.
25. Salvatore G, Nappi TC, Salerno P, et al A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res. 2007; 67(21): 10148-10158.
26. He H, Jazdzewski K, Liyanarachchi S., et al The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2005; 102: 19075-19080.
27. Hebrant A, Dom G, Dewaele M., et al. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One. 2012; 7: e37807.
28. Kim YN, Koo KH, Sung J.Y., Yun UJ, Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012; 2012: 306879.
29. Shankar J, Messenberg A, Chan J., Underhill TM, Foster LJ, Nabi IR. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010; 70: 3780-3790.
30. Kjellman P, Lagercrantz S, Hoog A., Wallin G, Larsson C, Zedenius J. Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes Chromosomes Cancer. 2001; 32: 43-49.
31. Zou M, AlBaradie RS, Al Hindi H, Farid NR, Shi Y. S100A4(Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer. 2005; 93: 1277-1284.
32. Nipp M, Elsner M, Balluff B., et al S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. J Mol Med (Berl). 2012; 90: 163-174.
33. Caccia D, Zanetti DL, Micciche F, et al Secretome compartment is avaluable sourceofbio markers for cancer-relevant pathways. J Proteome Res. 2011; 10: 4196-4207.
34. Hao J, Wang K, Yue Y., et al. Selective expression of S100A11 in lung cancer and its role in regulating proliferation of adenocarcinomas cells. Mol Cell Biochem. 2012; 359: 323-332.
35. Ito Y, Yoshida H, Tomoda C., et al Expression of S100A2 and S100A6inthyroid carcinomas. Histopathology. 2005; 46: 569-575.
36. Pilli T, Prasad KV, Jayarama S, Pacini F., Prabhakar BS Potential utility and limitations of thyroid cancercelllinesas models for studying thyroid cancer. Thyroid. 2009; 19: 1333-1342.
37. Degl'Innocenti D, Alberti C, Castellano G, et al. Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas. PLoS One. 2010; 5(9): e12701.